CY1121406T1 - Διαγνωση καρδιακης ανεπαρκειας - Google Patents

Διαγνωση καρδιακης ανεπαρκειας

Info

Publication number
CY1121406T1
CY1121406T1 CY20191100229T CY191100229T CY1121406T1 CY 1121406 T1 CY1121406 T1 CY 1121406T1 CY 20191100229 T CY20191100229 T CY 20191100229T CY 191100229 T CY191100229 T CY 191100229T CY 1121406 T1 CY1121406 T1 CY 1121406T1
Authority
CY
Cyprus
Prior art keywords
heart failure
concentration
igfbp2
diagnosis
patient
Prior art date
Application number
CY20191100229T
Other languages
English (en)
Inventor
Philippe Rouet
Fatima SMIH-ROUET
Franck Desmoulin
Michel Galinier
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm) filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of CY1121406T1 publication Critical patent/CY1121406T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/4473—Arrangements for investigating the separated zones, e.g. localising zones by electric means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • External Artificial Organs (AREA)
  • Paper (AREA)

Abstract

Η εφεύρεση σχετίζεται με μια μέθοδο για ταξινόμηση ενός ασθενούς ο οποίος διατρέχει κίνδυνο για καρδιακή ανεπάρκεια, όπου η εν λόγω μέθοδος περιλαμβάνει τα στάδια (i) της μέτρησης της συγκέντρωσης της IGFBP2 σε ένα δείγμα το οποίο ελήφθη από τον εν λόγω ασθενή και (ii) της σύγκρισης της συγκέντρωσης της IGFBP2 η οποία μετρήθηκε στο στάδιο (i) με μια τιμή ελέγχου η οποία προέρχεται από την συγκέντρωση της IGFBP2 σε δείγματα από ασθενείς οι οποίοι βρίσκονται σε συγκεκριμένα στάδια καρδιακής ανεπάρκειας και/ή με μια τιμή ελέγχου η οποία προέρχεται από την συγκέντρωση της IGFBP2 σε δείγματα αίματος από υγιείς ασθενείς.
CY20191100229T 2012-08-09 2019-02-25 Διαγνωση καρδιακης ανεπαρκειας CY1121406T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305988 2012-08-09
EP13747847.5A EP2883057B1 (en) 2012-08-09 2013-08-09 Diagnostic of heart failure
PCT/EP2013/066697 WO2014023820A1 (en) 2012-08-09 2013-08-09 Diagnostic of heart failure

Publications (1)

Publication Number Publication Date
CY1121406T1 true CY1121406T1 (el) 2020-05-29

Family

ID=48953397

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100229T CY1121406T1 (el) 2012-08-09 2019-02-25 Διαγνωση καρδιακης ανεπαρκειας

Country Status (15)

Country Link
US (2) US20150219669A1 (el)
EP (1) EP2883057B1 (el)
JP (2) JP6298054B2 (el)
CY (1) CY1121406T1 (el)
DK (1) DK2883057T3 (el)
ES (1) ES2713098T3 (el)
HR (1) HRP20190341T1 (el)
HU (1) HUE042708T2 (el)
LT (1) LT2883057T (el)
PL (1) PL2883057T3 (el)
PT (1) PT2883057T (el)
RS (1) RS58553B1 (el)
SI (1) SI2883057T1 (el)
TR (1) TR201902555T4 (el)
WO (1) WO2014023820A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014195456A1 (en) 2013-06-06 2014-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker of rehospitalization after heart failure

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
EP1722232A1 (en) 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
US20080166734A1 (en) * 2005-12-21 2008-07-10 David Xing-Fei Deng Genes and methods of using the same for diagnosis and for targeting the therapy of cardiovascular disease
CA2655997A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
CA2671298C (en) * 2007-01-25 2020-07-28 F. Hoffmann-La Roche Ag Use of igfbp-7 in the assessment of heart failure
EP2310860A1 (en) * 2008-07-30 2011-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Blood glutathione as a biomarker for screening asymptomatic patients at risk for heart failure
RU2013103995A (ru) * 2010-07-14 2014-08-20 Коммонуэл Сайентифик энд Индастриз Рисерч Организейшн Диагностика колоректального рака
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
EP2841945A4 (en) 2012-04-24 2016-04-27 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING OF STROKE OR OTHER BRAINS
US20140206632A1 (en) * 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease

Also Published As

Publication number Publication date
JP6595641B2 (ja) 2019-10-23
US11061037B2 (en) 2021-07-13
JP6298054B2 (ja) 2018-03-20
EP2883057A1 (en) 2015-06-17
EP2883057B1 (en) 2018-12-05
US20180143208A1 (en) 2018-05-24
HRP20190341T1 (hr) 2019-05-31
JP2015528562A (ja) 2015-09-28
SI2883057T1 (sl) 2019-07-31
LT2883057T (lt) 2019-04-25
ES2713098T3 (es) 2019-05-17
PT2883057T (pt) 2019-03-06
PL2883057T3 (pl) 2019-07-31
WO2014023820A1 (en) 2014-02-13
HUE042708T2 (hu) 2019-07-29
RS58553B1 (sr) 2019-05-31
DK2883057T3 (en) 2019-03-18
TR201902555T4 (tr) 2019-03-21
JP2018109640A (ja) 2018-07-12
US20150219669A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
CY1121872T1 (el) Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
CY1118888T1 (el) Μεθοδος αναγνωρισης, επιλογης και αναλυσης καρκινικων κυτταρων
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
CY1117095T1 (el) Συσκευη και μεθοδος για ηλεκτροχημικη ανιχνευση
MX2016006252A (es) Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono.
BR112013010023A2 (pt) algoritimo aperfeiçoado para a detecção de diabetes
CY1119262T1 (el) Αναλυτικες μεθοδοι και συστοιχιες για χρηση στην ταυτοποιηση παραγοντων που επαγουν ευαισθητοποιηση στο ανθρωπινο δερμα
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
CY1121916T1 (el) Βιοδεικτες micro-rna για την ταυτοποιηση του κινδυνου και/ή τη διαγνωση του ογκου στον πνευμονα
CY1120731T1 (el) Θεραπευτικη αγωγη κατα του καρκινου
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
RU2013138721A (ru) Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
CY1122033T1 (el) Μεθοδοι για την αυξηση του βιaιa εκπνεομενου ογκου σε ασθματικους με τη χρηση μπενραλιζουμαμπης
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
CY1121406T1 (el) Διαγνωση καρδιακης ανεπαρκειας
EA201690537A1 (ru) Способы и средства для введения контрастной среды
EA201491780A1 (ru) Мутанты c-raf, придающие резистентность к ингибиторам raf
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
CY1114910T1 (el) Βιοδεικτης για παρακολουθηση ασθενων